Scientists in Perelman School of Medicine at the University of Pennsylvania have been working to produce a vaccine for the herpes simplex virus 2.
This new vaccine implements the “trivalent” approach which allows the body to produce antibodies against three separate aspects of the virus, two of which would normally allow the virus to evade the body’s immune system. So far there has been great success with the vaccine.
It’s currently estimated that 500 million people are infected with the HSV2 and can be potentially lethal to infants born to infected mothers.
The results with both guinea pigs and macaque monkeys have been promising. Currently, there is no other candidate with the success that this vaccine has seen so far in testing. It could potentially lead the fight to stop the spread of the HSV2, of course, we have to wait for the full trials to be over and the FDA approval before it comes to the market.
Read the full article here:
https://www.sciencedaily.com/releases/2017/01/170119163444.htm
